Adrenergic stimulation of LRM55 glial cells results in the release of the neuroactive amino acid taurine.
Specific receptors for a number of neurotransmitters have been identified on glial cells. The best studied of these has been the padrenergic receptor (see "Discussion"); however, muscarinic acetylcholine (Repke and Maderspach, 1982) serotonin (Tardy et al., 1982) glutamate (Bowman and Kimelberg, 1984) histamine (Hosli et al., 1984) and a variety of peptide receptors (Van Calker and Hamprecht, 1980; Perrone et al., 1983; Rougon et al., 1983) have also been described. More than one of these receptors have been studied as regulators of cyclic adenosine 3',5'-monophosphate (CAMP). Although @-adrenergic stimulation of CAMP has been correlated with increased glycogenolysis in primary cultures of astrocytes (Opler and Makman, 1972) and induction of lactic dehydrogenase in a glial cell line (devellis and Brooker, 1972 ) the physiological consequences of such changes for glial cell function in the CNS are not well understood.
Glial cell function can be studied using primary cultures and continuous cell lines. The LRM55 glial cell line studied in our laboratory was obtained from a single cell clone (Martin and Shain, 1979) from an ethyl nitrosourea-induced rat spinal cord tumor (Morantz et al., 1978) . This cell line exhibits a number of glial properties, including astrocytic morphology, high affinity transport of the amino acid neurotransmitters taurine and glutamate (Martin and Shain, 1979; Waniewski and Martin, 1983) , nonexcitable membrane properties similar to those reported for glia (Seligmann et al, 1979) anion exchange and transport mechanisms (Wolpaw and Martin, 1982) the presence of glial fibrillary acidic protein (W. Shain, unpublished observation) , and synthesis of a glial cell growth factor (Sakazaki et al., 1982) .
Recent studies with LRM55 glial cells demonstrated that the stimulation of adrenergic (Shain et al., 1983; Shain and Martin, 1984) and K-opiate receptors stimulate the specific release of the Inhibitory neuroactive amino acid taurine.
The present study was undertaken to measure the binding kinetics and pharmacological properties of adrenergic receptors on LRM55 glial cells and to describe the relationship between receptor occupancy, intracellular CAMP accumulation, and release of taurine.
Materials and Methods
Chemfcals.
( (Vogel et al., 1972) IPR and other drugs to be tested for CAMP stimulation were dissolved in HHA. All stimulation experiments were performed at 37°C. Monolayers of cells were washed three times with 1 -ml portions of HH exposed to 250 ~1 of IPR (or combinatron of drugs) for exactly 1 min (or specified time). The incubation mixture was asprrated and replaced by 400 ~1 of 6% trichloroacetic acid (TCA). One hundred mrcrolrters of tritiated CAMP recovery marker were added to each well and the contents were sonicated and transferred to a centrifuge tube. Each well was washed with two additional 250.~1 portions of TCA, and the TCA precipitate was separated from the supernatant by centrifugation. The TCA supernatant (500 ~1) was then extracted three times with water-saturated ether, the ether phase was drscarded, and the water phase was evaporated to dryness and tested for CAMP content after reconstitution in sodium acetate buffer according to kit instructrons.
Protein contents were determined on total cells per well dissolved in 0.4 N NaOH. Protein and CAMP measurements were performed on triplicate wells.
Taurine release. Release of taurine was measured as described previously (Shain and Martin, 1984) . Incubations and perfusions were carried out in HHA. In a typical experiment, cells grown on a cell support film were incubated with [3H]taurine (10 pCr/ml of HHA) for 60 min, mounted in glass columns, and perfused with HHA initially and between drug applications. IPR or other drugs were applied for 3 min. One-minute (0.5 ml) fractions were Vol. 5, No. 12, Dec. 1985 samples; all others were from dupkate samples.
collected throughout and counted for radioactivity. At the end of the run, the strip of cells was removed from the column and used to measure total remaining radroactivity.
To normalize values from various perfusions, a 10e7 M IPR applrcation was included as a point of reference in most experiments. Protein. Protein concentratrons were determined by the dye-binding method (Bradford, 1976) with bovine serum albumin as the standard.
Results
Kinetics of binding. Specific binding of ["'l] IHYP to LRM55 cell preparations was dependent on protein concentration, temperature, and ligand concentration. Within the range tested (10 to 100 pg of protein/tube), specific binding increased linearly with increasing protein concentration (data not shown).
Binding was both time and temperature dependent. At 37°C and 24 PM ['z51]IHYP, total binding rose sharply during the first few minutes, then continued to increase at a reduced rate (Fig. 1) . Nonspecific binding also rose sharply during the first few minutes but leveled off around 3 min and remained constant throughout the experiment. Under these conditions specific binding reached halfsaturation within 10 min and 80 to 90% saturation by 30 min.
Equilibrium binding. As shown in Figure 2 , at equilibrium, nonspecific binding increased linearly with increasing ligand concentration, total binding increased nonlinearly, and both appeared to be nonsaturable. Specific binding therefore increased rapidly at first and then reached a plateau near 200 PM ['z51]IHYP. K,,, and B,, values from these equilibrium studies (Fig. 2, inset ) (Fig. 3) . As expected, the /3-antagonist PROP was a much more potent inhibitor than the @-agonist IPR. Both compounds showed marked stereoselectivity with the (-)-isomers 10 to 50 times more potent than their (+)-counterparts CAMP accumulation. In order to prevent degradation of CAMP formed due to phosphodiesterase (PDE) acivity, stimulation studies of CAMP are frequently performed in the presence of a PDE inhibitor. Thus, the intracellular accumulation of CAMP was followed as a function of time of exposure to IPR in the absence and presence of the PDE inhibitor RO 20-1724 (Fig. 4) . The time course is characterized by a sharp rise during the first few minutes of exposure to agonist followed by a gentle decline to a new level appreciably higher than the base line. The presence of RO 20-1724 in the incubation mix resulted in greater accumulation of CAMP even at early times, and this effect became more pronounced at later times (Fig. 4, inset) . However, since inclusion of the PDE inhibitor was not necessary to detect measurable amounts of CAMP, RO-1724 was omitted from routine experiments to parallel conditions used for taurine release. Standard assays used 1 -min exposure times.
Taurine release. When LRM55 glial cells were exposed to IPR, there was a time-and dose-dependent release of taurine. Figure 5 shows a series of release profiles with increasing times of exposure to lo-' M IPR. It is clear that the peaks broaden and eventually develop a distinct shoulder as exposure time is increased. The relationship between length of exposure period and stimulated taurine release is linear from 1 to 10 min, but with longer application The Journal of Neuroscience Taurine Release from LRM55 Glial Cells periods there is an attenuation of taurine release (Fig. 5, inset) . Because the present studies focus on the activation of taurine release, a 3-min exposure to IPR was used for routine assays.
Comparison of time courses of CAMP accumulation and taurine release. Since P-adrenergic stimulation of LRM55 cells results in increased CAMP accumulation and release of taurine, parallel experiments were designed to measure the intracellular accumulation of CAMP and the rate of taurine release at specific times after application of lo-' M IPR. These time courses are remarkably similar (Fig.  6 ): they both rise rapidly in response to IPR stimulation, reach a maximum by 2 to 3 min, and decline thereafter. The rate of decline for release appears to be greater than that for the decline of intracellular CAMP.
Pharmacology. Three adrenergic agonists (IPR, NE, and E) were compared in experiments designed to describe the pharmacology of (a) receptor occupancy as measured by specific ['251]IHYP binding, (b) adenylate cyclase activation as measured by increases in intracellular accumulation of CAMP, and (c) taurine release (Fig. 7) . Of these, IPR was the most potent inhibitor of ['251]IHYP binding and stimulation of CAMP accumulation and taurine release. NE and E were about equipotent as inhibitors of ['251]IHYP binding (Fig. 7A ) and stimulators of taurine release (Fig. 7C) ; however, E was significantly more potent in stimulating CAMP accumulation than was NE (Fig. 7B) . The high potency of IPR is expected of p-but not o(-adrenergic receptors (Lands et al., 1967 ). The P-adrenergic nature of these receptors was further demonstrated by comparing the effect of two p-antagonists, ALP and PROP, and the a-antagonist PHENT on specific ['251]lHYP binding, CAMP contents, and taurine release. The two @-antagonists were Table I ) can be used to make the following obervations on the relationship of receptor-mediated CAMP accumulation and taurine release. (7) E& values for agonists are greater for CAMP accumulation than for taurine release, indicating that taurine release is a more sensitive measure of P-receptor stimulation of adenylate cyclase activation than is measurement of intracellular CAMP. A small amount of CAMP accumulation may be sufficient to stimulate taurine release, resulting in a shift in the release dose response curve to the left. (2) I& values for antagonists are nearly identical for receptormediated CAMP accumulation and taurine release. Since I&,, values for PROP, ALP, and PHENT are measures of the competition between the antagonists and the agonist IPR for receptor-binding sites, the similar I&, values for CAMP accumulation and taurine releases indicate that the same population of receptors is involved with both cellular responses.
These observations and the similarity of the CAMP and taurine release time courses are consistent with the hypothesis that there is a causal relationship between these two events. To directly test this hypothesis, membrane-permeable, nonhydrolyzable analogues of CAMP were used as potential secretagogues.
Application of db-CAMP resulted in a dose-dependent increase in taurine release ( Fig.  9 ) with a maximal effect at 10m3 M. Similarly, 8-Br-CAMP also stimulated taurine release (data not shown).
Discussion
Receptors on LRM55 cells characterized in the present study by grown in 24-well dishes were washed and exposed to 10e7 M IPR for the indrcated lengths of time. CAMP concentrations (0) were measured as described prevrously and expressed as a percentage of the maxrmal value obtatned. For taurine release (0) cells on support film were mounted tn the perfusron chamber, washed with buffer, and exposed to lo-' M IPR contrnuously for 15 min. One-minute (0.5 ml fractions were collected and counted for radroactivrty; release is expressed as percentage of the maximal value obtarned. (Schmitt and Pochet, 1977) for intact C6 cells, and 250 PM (Maguire et al., 1976a) for C6 membrane preparations. For human astrocytes (Johnson et al., 1978 ) the reported KD is 73 PM. The calculated B,, for LRM55 cells is 52.1 ? 5.0 fmol/mg of protein (5600 sites/cell). Similar amounts of binding have been reported for other glial cells. For the C6 cell line binding ranges from 75 fmol/mg of protein, or 4000 sites/cell (Maguire et al., 1976b) , to 7000 sites/cell (Schmitt and Pochet, 1977) or approximately 131 fmol/mg of protein (assuming IO' cells = 1 mg of protein). The B,, reported for human astrocytes is 186 fmol/mg of protein (Johnson et al., 1978) . ['251 ] IHYP binding to LRM55 cells is also highly stereoselective. The rank order of specific binding inhibition by agonists (IPR > E 2 NE) and antagonists (ALP and PROP > PHENT) is characteristic of a P-type system. Stimulation of LRM55 cells by IPR, NE, and E results in elevated levels of intracellular CAMP. Since Gilman and Nirenberg (1971) first demonstrated.an elevation of intracellular CAMP in three glial cell lines after stimulation by NE and IPR, cyclase activation has been extensively studied in glia (references above; Browning et al., 1976; Franklin and Twose, 1976; McCarthy and devellis, 1978; Su et al., 1979; Moylan et al., 1982) . The pharmacology of agonist-stimulated CAMP accumulation and the inhibition pattern of the antagonists show a P-pattern consistent with the ["51]IHYP binding results.
Taurine release from LRM55 cells is also stimulated by IPR, NE, and E. The rank order of potency of these agonists (IPR > E 2 NE) indicates that release is the result of P-stimulation. Additional evidence that this stimulation occurs via D-receptor activation is provided by antagonist pharmacology. ALP and PROP, P-antagonists, effectively inhibit IPR-stimulated taurine release, but the a-antagonist Figure 78 , the 100% control value being that obtained by lo-' M IPR stimulation in the absence of other drugs. C, Cells grown on support film and mounted in the perfusion chamber were exposed to lo-' M IPR first (control), then to a mixture of 10e7 M IPR and various concentrations of antagonists for 3 min, followed by 17.min buffer washes, Total taurine release for each drug concentration was measured as in Figure 7C and [d bc Figure 9 . Effect of db-CAMP on taurine release. Cells grown on support film were incubated with [3H]taurine, mounted In the perfusion chamber, and perfused with increasing concentratrons of db-CAMP for 3-min periods. Onemrnute (0.5 ml) fractions were collected, and total taurine released by each db-CAMP application is expressed as counts per minute. receptor occupancy, (b) elevation of intracellular CAMP levels, and (c) release of taurine.
Taurine can be found in high concentration in the brain and causes increased Cl-permeability when applied to neurons (Okamoto et al., 1983) . Thus, taurine might be an important inhibitory neuroregulator.
Our results with LRM55 glial cells and primary cultures (Shain and Martin, 1984) demonstrate that receptor-mediated taurine release is a glial cell function.
Glia can therefore respond to neuronal transmitters by releasing taurine and thereby regulate neuronal activity.
